Navigation Links
Vasogen Announces Third Quarter 2007 Results

transplantation, led

Vasogen's 2,400-patient ACCLAIM study, which was completed last year.

We are also pleased to announce the other members of the newly formed

ACCLAIM-II steering committee include Guillermo Torre-Amione, MD,

PhD, FACC, Medical Director, Heart Transplant Program, Methodist

DeBakey Heart Center at The Methodist Hospital; Robert Bourge, MD,

Professor & Director of Cardiology Division, Department of Medicine,

University of Alabama at Birmingham; Jean Rouleau, MD, Dean of

Medicine, University of Montreal; Maria Rosa Costanzo, MD, Medical

Director, Edward Center for Heart Failure, Midwest Heart Foundation;

Clyde W. Yancy Jr., MD, Medical Director, Baylor Heart & Vascular

Institute; and Mariell Jessup, MD, Medical Director, Hospital of the

University of Pennsylvania, Heart Failure/Transplant Center.

- A medical symposium focused on the introduction of our

Celacade technology into the European Union was recently held during

the 11th National Conference of Advanced Therapies in Heart Failure

in Spain. The symposium, which was hosted by our European

commercialization partner, Grupo Ferrer Internacional, S.A.

("Ferrer"), was attended by physicians whom Ferrer is targeting to

participate in the initial roll-out of our Celacade technology for

the treatment of heart failure patients. Ferrer is initially

targeting Germany and Spain for the initial commercial launch of

Celacade. Among the presenters at the symposium was Dr. Torre-Amione,

who discussed the importance of the role inflammation plays in the

development and progression of heart failure, and who also reviewed

the results of the ACCLAIM trial of Celacade in chronic heart

failure. The European commercialization activities for Celacade are


SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at , ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... A study published online today in Genome Research ... evolutionary conservation of the genes and pathways associated with ... aging-related genes in simple model organisms that may lead ... in human aging and age-associated diseases. , While nearly ...
... (Nasdaq: EXEL ) announced today that George A. ... present at the,Cowen and Company Annual Health Care Conference ... March 17, 2008. Dr. Scangos will discuss updates to ... will be webcast and may be accessed in the ...
... March 12 UCT Specialties LLC is now,offering their ... years of,experience in research and development and with input ... for many years, each guide is,designed to illustrate and ... the products it represents., With thousands of calls ...
Cached Biology Technology:Growing old together: Yeast, worms and people may age by similar mechanisms 2UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings 2
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... spring weather in 2010 and 2012 resulted in the earliest ... two sites in the eastern US, according to research published ... by Elizabeth Ellwood of Boston University and colleagues. ... changes that make them bloom in the spring. According to ...
... and Barry Magee from Queen,s School of Biological Sciences ... small electrical shocks, and their behaviour after experiencing those ... Journal of Experimental Biology ., Professor Elwood,s previous research ... way consistent with pain. This latest study provides further ...
... is increasing from multiple scientific fields that exposure to the ... by the U.S. Forest Service, the presence of trees was ... forester at the Forest Service,s Pacific Northwest Research Station, and ... eastern and midwestern United States was an unprecedented opportunity to ...
Cached Biology News:'Shell-shocked' crabs can feel pain 2Tree and human health may be linked 2
... includes 2 tube gel adaptors, 24 ... length), gaskets, grommets, stoppers. The PROTEAN II ... cell offer the versatility to perform a ... second-dimension 2-D electrophoresis, native, preparative, and gradient ...
StemSep Anti-Phycoertherin Tetrameric Antibody Complexes, 2 mL for labeling 1x10 9 cells. Cross-linking Reagent for StemSep Separations of Cells Labeled with PE-conjugated Antibody....
... The PROTEAN II XL cell, wide format, is used ... x 20 cm gels and requires 1.2 L of ... unit and the 2.0 mm IPG conversion kit, which ... and includes 2 sets of IPG clamps, 2 sets ...
... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
Biology Products: